BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16430107)

  • 1. [Prevention of cardiovascular events by the antihypertensive treatment using amlodipine and perindopril in comparison with the use of atenolol and bendroflumethiazide. The ASCOT (Anglo-Scandinavian Outcomes Trail: blood pressure lowering arm) study results--multicentre, randomised, controlled trial. Landmark in the development of opinions on combination therapy in hypertension? (comment)].
    Widimský J
    Vnitr Lek; 2005 Dec; 51(12):1394-6, 1398-9. PubMed ID: 16430107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
    J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
    Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
    Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
    J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].
    van den Meiracker AH; van Montfrans GA
    Ned Tijdschr Geneeskd; 2006 Apr; 150(16):886-8. PubMed ID: 16686086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
    Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR;
    Diabetes Care; 2008 May; 31(5):982-8. PubMed ID: 18235048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
    Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
    Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and hypertension: which is the best approach?
    Escobar C; Barrios V
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):269-71. PubMed ID: 19296764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
    Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
    Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
    Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
    J Hypertens; 2011 Mar; 29(3):583-91. PubMed ID: 21297503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the ASCOT-BPLA trial: no practical implications for treatment of hypertension.
    Prescrire Int; 2006 Jun; 15(83):112. PubMed ID: 16764103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new dimension in hypertension management with the amlodipine/perindopril combination.
    Poulter NR
    J Hypertens; 2011 Dec; 29 Suppl 1():S15-21. PubMed ID: 22157563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
    Coleman JJ; Kendall MJ
    J Clin Pharm Ther; 2006 Aug; 31(4):299-307. PubMed ID: 16882098
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
    Chalmers J; Joshi R; Kengne AP; Ninomiya T; Bi Y; Bompoint S; Billot L; Patel A;
    J Hypertens Suppl; 2008 Sep; 26(3):S21-7. PubMed ID: 19363849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary heart disease benefits from blood pressure and lipid-lowering.
    Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
    Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
    Waeber B
    J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.